Wolfgang Peter Fendler, MD; Department of Molecular and Medical Pharmacology and David Geffen School of Medicine at UCLA will be discussing diagnosing and treating prostate cancer with radioactive drugs directed at the prostate-specific membrane antigen (PSMA).
Despite recent advances, metastatic prostate cancer remains a significant diagnostic and therapeutic challenge. The specific cell surface receptor, prostate-specific membrane antigen (PSMA), is present at high levels in metastatic prostate cancer making it an attractive target. Radioactive drugs were developed over the past years that bind firmly to PSMA. Depending on the type of radioactivity these ligands can be applied for imaging (positron emission for positron emission tomography, PET/CT) or therapy (electron emission for radioligand therapy, RLT). PSMA-directed PET/CT demonstrates the highest rates for tumor detection in patients with rising PSA level after intial therapy. PSMA-directed RLT effectively lowers PSA and induces tumor shrinkage in patients with advanced metastatic disease. Both procedures are well tolerated. Based on these promising data, UCLA will offer both PSMA PET/CT and RLT to patients within clinical trials.